ArticleScientific reports2025
Upper limb function and quality of life in Duchenne muscular dystrophy: a cross-sectional study in Chile.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Duchenne muscular dystrophy (DMD) impairs motor function and health-related quality of life (HRQoL), yet data from low- and middle-income countries are scarce. We assessed upper limb functionality with the Upper Limb Functionality Evaluation Scale (EEFES) and HRQoL with the SF36v2 in Chilean patients with DMD at late ambulatory and nonambulatory stages, comparing them with healthy age-matched controls. This cross-sectional study included 17 patients with genetically or biopsy-confirmed DMD and 12 controls. Median upper limb functionality was 51%; proximal domains were most impaired (0%) while distal domains remained preserved (100%). Compared with controls, patients reported markedly lower physical functioning (15% vs. 100%) and general health (62% vs. 82%), with a reduced physical component summary (40 vs. 58), but higher mental component summary (58 vs. 50). Age correlated negatively with upper limb performance (ρ = - 0.73; p = 0.0013), whereas corticosteroid use correlated positively (ρ = 0.73; p = 0.0163). Physical Function 10 (PF10) and General Health 2 items showed the strongest associations with upper limb performance. In this first Chilean cohort using EEFES and SF36v2, DMD patients demonstrated significant physical but relatively preserved mental health. These findings align with international reports and highlight potential sensitive endpoints for clinical trials in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.